Type I interferon signature in the initiation of the immune response in vitiligo

Authors

  • Antoine Bertolotti,

    1. Department of Dermatology and Pediatric Dermatology, National Centre for Rare Skin Disorders, Saint-André and Pellegrin Hospital, Bordeaux, France
    Search for more papers by this author
  • Katia Boniface,

    1. INSERM U1035, Immunodermatology Team, Université Bordeaux Segalen, Bordeaux, France
    Search for more papers by this author
  • Beatrice Vergier,

    1. Department of Pathology, Haut-Lévèque Hospitals, Pessac, France
    Search for more papers by this author
  • Djavad Mossalayi,

    1. INSERM U1035, Immunodermatology Team, Université Bordeaux Segalen, Bordeaux, France
    Search for more papers by this author
  • Alain Taieb,

    1. Department of Dermatology and Pediatric Dermatology, National Centre for Rare Skin Disorders, Saint-André and Pellegrin Hospital, Bordeaux, France
    2. INSERM U1035, Immunodermatology Team, Université Bordeaux Segalen, Bordeaux, France
    Search for more papers by this author
  • Khaled Ezzedine,

    1. Department of Dermatology and Pediatric Dermatology, National Centre for Rare Skin Disorders, Saint-André and Pellegrin Hospital, Bordeaux, France
    2. INSERM U1035, Immunodermatology Team, Université Bordeaux Segalen, Bordeaux, France
    Search for more papers by this author
  • Julien Seneschal

    Corresponding author
    1. Department of Dermatology and Pediatric Dermatology, National Centre for Rare Skin Disorders, Saint-André and Pellegrin Hospital, Bordeaux, France
    2. INSERM U1035, Immunodermatology Team, Université Bordeaux Segalen, Bordeaux, France
    Search for more papers by this author

Summary

Immune-mediated responses are consistently observed in progressing vitiligo at the edge of depigmenting patches. Besides the role of the adaptive immune system, the profile of the innate immune response is now at the center of the stage. We report that plasmacytoid dendritic cells (pDC), which are the major interferon (IFN)-alpha-producing cells, are part of the infiltrate of progressive vitiligo with local production of MxA (a protein induced by IFNα). MxA was associated with expression of the type I IFN-inducible ligand CXCL9 and correlated with the recruitment of CXCR3+ immune cells. Interestingly, strong MxA expression was observed in perilesional skin in close apposition to remaining melanocytes, surrounded by a prominent T-cell infiltrate. In contrast, MxA was not detectable in lesional skin, suggesting that IFN-α production is an early event in the progression of the disease. Our data highlight a new innate immune pathway leading to progression of vitiligo.

Ancillary